GSK's critics reject company's much-touted turnaround

The New York Times examines GlaxoSmithKline's insistence that it is on the road to recovery as it rebounds from a series of setbacks and declining profits from some key blockbusters. Company executives insist that GSK has 15 top drugs in late-stage development, part of 147 trials underway. But several market analysts say that GSK is being beaten to the drug market by its competitors, has several drugs that aren't living up to expectations and has never successfully reorganized its research division since the big merger between Glaxo Wellcome and SmithKline Beecham five years ago.

- read this story from The New York Times for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.